Relevant bibliographies by topics / Cancer – Adjuvant treatment

Academic literature on the topic 'Cancer – Adjuvant treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer – Adjuvant treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer – Adjuvant treatment"

1

Rubens, R. D. "Breast cancer: Adjuvant treatment." European Journal of Cancer 28, no. 2-3 (February 1992): 620–22. http://dx.doi.org/10.1016/s0959-8049(05)80111-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

McClellan, M. B. "Adjuvant Breast Cancer Treatment." JAMA: The Journal of the American Medical Association 288, no. 17 (November 6, 2002): 2112—a—2112. http://dx.doi.org/10.1001/jama.288.17.2112-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

McClellan, Mark B. "Adjuvant Breast Cancer Treatment." JAMA 288, no. 17 (November 6, 2002): 2112. http://dx.doi.org/10.1001/jama.288.17.2112-jfd20011-2-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wolpin, B. M., J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer. "Adjuvant Treatment of Colorectal Cancer." CA: A Cancer Journal for Clinicians 57, no. 3 (May 1, 2007): 168–85. http://dx.doi.org/10.3322/canjclin.57.3.168.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Agboola, Olu. "Adjuvant treatment in gastric cancer." Cancer Treatment Reviews 20, no. 3 (July 1994): 217–40. http://dx.doi.org/10.1016/0305-7372(94)90001-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Neoptolemos, John P. "Adjuvant treatment of pancreatic cancer." European Journal of Cancer 47 (September 2011): S378—S380. http://dx.doi.org/10.1016/s0959-8049(11)70210-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wils, J. A. "Adjuvant treatment of colorectal cancer." Acta chirurgica Iugoslavica 49, no. 2 (2002): 15–18. http://dx.doi.org/10.2298/aci0202015w.

Full text
Abstract:
Colorectal cancer is a leading cause of morbidity and mortality, with approximately 300,000 new cases and 200,000 related deaths in Europe and the USA each year. Adjuvant treatment of colorectal cancer is now widely accepted and can reduce mortality with approximately 10%. This can be considered as one of the major achievements in oncology from the past decade. Current results will be discussed and strategies for the future will be outlined, including on-going or planned large-scale trials with new drugs and approaches.
APA, Harvard, Vancouver, ISO, and other styles
8

Klaiber, Ulla, Thilo Hackert, and John P. Neoptolemos. "Adjuvant treatment for pancreatic cancer." Translational Gastroenterology and Hepatology 4 (April 2019): 27. http://dx.doi.org/10.21037/tgh.2019.04.04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Midgley, R. S., and D. J. Kerr. "Adjuvant treatment of colorectal cancer." Cancer Treatment Reviews 23, no. 3 (May 1997): 135–52. http://dx.doi.org/10.1016/s0305-7372(97)90035-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Passant, Helen, and Annabel Borley. "Adjuvant treatment for breast cancer." Surgery (Oxford) 28, no. 3 (March 2010): 140–43. http://dx.doi.org/10.1016/j.mpsur.2009.11.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer – Adjuvant treatment"

1

Wirth, Manfred P., and Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133839.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Smeenk, Henri Gerard. "Surgical and adjuvant treatment of pancreatic cancer." [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2008. http://hdl.handle.net/1765/13713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bossaer, John B., and Christian M. Thomas. "Adjuvant Treatment of Newly Diagnosed Breast Cancer." Digital Commons @ East Tennessee State University, 2011. https://dc.etsu.edu/etsu-works/2313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wirth, Manfred P., and Michael Fröhner. "Perspectives in Adjuvant Treatment of Prostate Cancer." Karger, 2002. https://tud.qucosa.de/id/qucosa%3A27540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Buijs, Ciska. "Long-term side effects of adjuvant breast cancer treatment." [S.l. : Groningen : s.n. ; University Library of Groningen] [Host], 2008. http://irs.ub.rug.nl/ppn/306087480.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Giallourou, Natasa. "Watercress as a nutritional adjuvant treatment in breast cancer." Thesis, University of Reading, 2017. http://centaur.reading.ac.uk/76171/.

Full text
Abstract:
Breast cancer is a leading cause of cancer related mortality globally, and epidemiological studies suggest a link between healthy nutrition and cancer prevention. Members of the Brassicaceae family, including watercress, have been extensively studied for their anti-cancer and anti-genotoxic potential. Watercress has a complex phytonutrient profile characterised by high levels of carotenoids, flavonols and glucosinolates. Extracts of watercress exhibit strong antioxidant capacity in vitro. Watercress and its components have been associated with the inhibition of the three stages of carcinogenesis: initiation, proliferation and metastasis in in vitro cancer cell models. Phenethyl isothiocyanate (PEITC) is a glucosinolate break-down product and watercress is the richest dietary source of it. It has received considerable attention for its anti-cancer properties and has been tested in a number of clinical trials. In this thesis, the effects of crude watercress extract and PEITC on the metabolic and phenotypic responses in breast cancer and healthy breast tissue cell lines were examined. Radiotherapy is the most common treatment modality for breast cancer patients; it functions by killing cancer cells but it simultaneously damages healthy tissues. We set out to examine synergistic responses to irradiation and watercress or PEITC exposures in breast cancer cells and we further investigated whether watercress or PEITC can be protective against radiation induced collateral damage. Watercress and PEITC effectively modulated important cancer cell metabolic pathways associated with anti-cancer endpoints such as cell cycle arrest and DNA damage. In this thesis, PEITC has been shown to enhance the sensitivity of cancer cells to irradiation making the cancer killing process more effective, whereas watercress can protect healthy breast cells from radiation induced damage. These observations appear to be mediated by the ability of PEITC and other phytochemicals in watercress to interact with the antioxidant glutathione. The results obtained from this work remain to be validated in a clinical setting.
APA, Harvard, Vancouver, ISO, and other styles
7

Wirth, Manfred P., and Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133890.

Full text
Abstract:
The guidelines for the curative treatment of prostate cancer presented by the German Society of Urology are discussed. They are based on the current knowledge of the outcomes of surgical and radiotherapeutic treatment for prostate cancer. Radical prostatectomy is recommended as the first-line treatment for organ-confined prostate cancer in patients with an individual life expectancy of at least 10 years. Radiotherapy can be considered as an alternative treatment modality, although current knowledge does not allow a definite assessment of the relative value of radiotherapy compared to radical prostatectomy. Locally advanced cT3 prostate cancer is overstaged in about 20% and curative treatment is possible in selected cases. Guidelines represent rules based on the available evidence. This implies that exceptions must be made whenever appropriate and that guidelines have to be reviewed regularly as new information becomes available
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
8

Wirth, Manfred P., and Michael Fröhner. "Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133551.

Full text
Abstract:
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam radiotherapy series with locally advanced and probably mainly micrometastatic tumors. The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy. At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm (hazards ratio 0.58, 95% confidence interval 0.51–0.66, p < 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
9

Wirth, Manfred P., and Michael Fröhner. "Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program." Karger, 2003. https://tud.qucosa.de/id/qucosa%3A27515.

Full text
Abstract:
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam radiotherapy series with locally advanced and probably mainly micrometastatic tumors. The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy. At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm (hazards ratio 0.58, 95% confidence interval 0.51–0.66, p < 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
10

Wirth, Manfred P., and Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer." Karger, 1999. https://tud.qucosa.de/id/qucosa%3A27546.

Full text
Abstract:
The guidelines for the curative treatment of prostate cancer presented by the German Society of Urology are discussed. They are based on the current knowledge of the outcomes of surgical and radiotherapeutic treatment for prostate cancer. Radical prostatectomy is recommended as the first-line treatment for organ-confined prostate cancer in patients with an individual life expectancy of at least 10 years. Radiotherapy can be considered as an alternative treatment modality, although current knowledge does not allow a definite assessment of the relative value of radiotherapy compared to radical prostatectomy. Locally advanced cT3 prostate cancer is overstaged in about 20% and curative treatment is possible in selected cases. Guidelines represent rules based on the available evidence. This implies that exceptions must be made whenever appropriate and that guidelines have to be reviewed regularly as new information becomes available.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cancer – Adjuvant treatment"

1

International Conference on the Adjuvant Therapy of Cancer. (5th 1987 Tucson, Ariz.). Adjuvant therapy of cancer V. Orlando: Grune & Stratton, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

International Congress on Neo-Adjuvant Chemotherapy (2nd 1988 Paris, France). Neo-adjuvant chemotherapy =: Chimiothérapie néo-adjuvante : proceedings of the first International Congress on Neo-Adjuvant Chemotherapy held in Paris (France), 19-21 February 1988. Paris: INSERM, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

International, Congress on Neo-Adjuvant Chemotherapy (2nd Paris France). Neo-adjuvant chemotherapy =: Chimiothérapie néo-adjuvante : proceedings of the Second International Congress on Neo-Adjuvant Chemotherapy held in Paris (France), 19-21 February 1988. London: Libbey, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

International, Congress on Neo-Adjuvant Chemotherapy (1st 1985 Paris France). Neo-adjuvant chemotherapy =: Chimiothérapie néo-adjuvante : proceedings of the first International Congress on Neo-Adjuvant Chemotherapy held in Paris (France), 6-9 November, 1985. London: Libbey, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1936-, Salmon S. E., ed. Adjuvant therapy of cancer VII: Proceedings of the Seventh International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, March 1993. Philadelphia: Lippincott, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Talking about treatment: Recommendations for breast cancer adjuvant therapy. New York: Oxford University Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

International, Conference on the Adjuvant Therapy of Cancer (6th 1990 Tucson Ariz ). Adjuvant therapy of cancer VI: Proceedings of the Sixth International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, March 7-10, 1990. Philadelphia: Saunders, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

International, Conference on the Adjuvant Therapy of Cancer (8th 1996 Scottsdale Ariz ). Adjuvant therapy of cancer VIII: Proceedings of the Eighth International Conference on the Adjuvant Therapy of Cancer, Scottsdale, Arizona, March, 1996. Philadelphia: Lippincott-Raven, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cancer, International Union against, ed. Rehabilitation and continuing care in cancer. Canforth, lancshire: Published on behalf of International Union Agianst Cancer [by] Parthenon Pub. Group, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

1944-, Arriagada R., Le Chevalier T, and International Association for the Study of Lung Cancer., eds. Treatment modalities in lung cancer. Basel: Karger, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer – Adjuvant treatment"

1

Barmpounis, Vasileios, and George Kesisis. "Planning Adjuvant Treatment." In Breast Cancer Essentials, 569–77. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73147-2_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jaffe, Norman. "Adjuvant Chemotherapy in Osteosarcoma." In Cancer Treatment and Research, 219–37. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-1-4419-0284-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Romond, Edward H., Lawrence A. Mendelsohn, and John S. MacDonald. "Adjuvant therapy of gastrointestinal cancer." In Cancer Treatment and Research, 273–95. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-2031-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Costa, Frederico, Gary Schwartz, and David Kelsen. "Adjuvant chemotherapy in gastric adenocarcinomas." In Cancer Treatment and Research, 41–63. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-4977-2_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Vergote, I. B., C. G. Tropé, L. N. De Vos, J. Kærn, V. M. Abeler, M. Winderen, and E. O. Pettersen. "Adjuvant treatment of ovarian carcinoma." In Cancer Treatment An Update, 464–68. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_96.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Oh, Do-Youn, and Yung-Jue Bang. "Adjuvant Treatment for Gastric Cancer." In Surgery for Gastric Cancer, 353–57. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-45583-8_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wils, J. A. "Adjuvant Treatment of Gastric Cancer." In Gastric Carcinoma, 135–39. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4612-3636-8_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ishikawa, Toshiaki, and Hiroyuki Uetake. "Adjuvant Chemotherapy." In Recent Advances in the Treatment of Colorectal Cancer, 81–100. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-3050-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zinser, J. W., N. Castañeda, A. Alfeirán, E. Maafs, M. Durán, G. Flores, R. Gaona, and L. Vicencio. "Treatment of osteosarcoma with Cisplatin and Doxorubicin either as Adjuvant or Neo-Adjuvant chemotherapy." In Cancer Treatment An Update, 565–67. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_120.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pollard, Annabel. "Supportive Care During Adjuvant Treatment." In Adjuvant Therapy for Breast Cancer, 219–38. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-75115-3_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer – Adjuvant treatment"

1

Jain, Vandana, Rupinder Sekhon, Shveta Giri, and Sudhir Rawal. "Role of radical surgery in early stages of vaginal cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685350.

Full text
Abstract:
Objectives: The objective of our present study was to evaluate the efficacy of radical vaginectomy with or without radical hysterectomy in patients with FIGO stage I and II vaginal cancers. Materials and Methods: A retrospective study was carried out on 13 patients aged 35 – 78 years. All the patients underwent radical surgery for vaginal cancer from April 2010 till June 2015. Kaplan- meier analyses was used to calculate the disease free survival and overall survival at 12 months. Results: The mean age of patients was 54.9 years. Twelve patients were with FIGO stage I while one had stage II vaginal cancer. The histopathology was squamous cell cancer in 9 patients, small cell neuroendocrine cancer in two patients and malignant melanoma in 2 patients. The lesion was confined to upper 2/3 of vagina in 8 cases and lower 1/3 was involved in 5 cases. All the patients underwent radical surgery. Lymph node dissection was done in eleven patients out of whom lymph nodes were positive in 4 patients. Three patients had positive margins. Adjuvant treatment was given to patients with positive margins or positive nodes. Six patients did not require any adjuvant treatment and two patients defaulted adjuvant treatment. One patient developed Vesico-vaginal fistula. Over a follow up period ranging from 6 to 67 months, recurrence developed in two patients and one of them died of disease. The 12 months Disease free survival was 82.1% and 12 months Overall Survival was 90.9%. Conclusion: Stage I and selected stage II vaginal cancer patients have good outcomes in terms of survival and local tumor control if managed judiciously by initial surgery followed by selective adjuvant therapy.
APA, Harvard, Vancouver, ISO, and other styles
2

Biegel, U., U. von Bodungen, K. Ruess, M. Reif, Y. Knauf, and N. Stratmann. "Mistletoe in adjuvant cancer treatment of companion animals." In 67th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA) in cooperation with the French Society of Pharmacognosy AFERP. © Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-3399644.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dall, P., T. Koch, G. Lenzen, T. Kuhn, C. Hielscher, D. Reichert, M. Maasberg, P. Ehscheidt, H. Eustermann, and G. Fischer. "P1-12-21: Adjuvant Trastuzumab Treatment without Adjuvant Chemotherapy in Early Breast Cancer." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p1-12-21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Goel, Raghav, Neha Shah, Rachana Visaria, Giulio F. Paciotti, and John C. Bischof. "Biodistribution of TNF-alpha Coated Gold Nanoparticles in an In Vivo Cancer Model." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192931.

Full text
Abstract:
Over the past several years, there has been an increasing interest in the use of nanoparticles as a tool for treatment of cancer. We have shown tremendous augmentation and control (without toxicity) of both heat and cold-based thermal therapy for cancer treatment with a gold based nanodrug-CYT-6091 (Cytimmune Sciences, Inc.) [1–3]. To reach the full potential of these nanodrugs for both stand-alone solid cancer treatment and as adjuvant to thermal therapy, there is a need to understand the in vivo biodistribution and their short-term and long-term tissue interaction.
APA, Harvard, Vancouver, ISO, and other styles
5

Hospodor, Andy D. "Abstract B83: Cannabinoids as an adjuvant therapy for pancreatic cancer." In Abstracts: AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.panca2014-b83.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Thomas, Susan N. "Targeting the Tumor-Draining Lymph Node With Adjuvant Nanoparticles for Cancer Immunotherapy." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14531.

Full text
Abstract:
Immunotherapy-based approaches for cancer treatment are of increasing clinical interest. Principles of drug delivery and the emerging field of material design for immunomodulation might hold significant promise for novel approaches in cancer immunotherapy since biomaterials engineering strategies enable enhanced delivery of immune modulatory agents to tissues and cells of the immune system1. One tissue of significant clinical interest in a cancer setting is the tumor-draining lymph node (TDLN), which participates in cancer progression by enabling both metastatic dissemination as well as tumor-induced immune escape. Hence, the TDLN represents a novel target for drug delivery schemes for cancer immunotherapy. We hypothesize that targeted delivery of adjuvants (Adjs) to the TDLN using a biomaterials-based approach might promote antitumor immunity and hinder tumor growth.
APA, Harvard, Vancouver, ISO, and other styles
7

Bianchini, G., L. Pusztai, T. Iwamoto, CM Kelly, M. Zambetti, A. Fasolo, G. Del Conte, L. Santarpia, WF Symmans, and L. Gianni. "S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-s1-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Han, Bumsoo, Matthew D. Egberg, Pung-Pung Haung, David J. Swanlund, and John C. Bischof. "Cryoinjury Enhancement of Breast Cancer Cells by Use of a Molecular Adjuvant (TNF-alpha)." In ASME 2004 International Mechanical Engineering Congress and Exposition. ASMEDC, 2004. http://dx.doi.org/10.1115/imece2004-61593.

Full text
Abstract:
Cryoinjury of human breast cancer cells (MCF7) in engineered tissue equivalents and the enhancement of the cryoinjury by use of a molecular adjuvant (tumor necrosis factor alpha, TNF-α) was studied. Tissue equivalents (TEs) were constructed by seeding MCF7 cells in collagen solutions at the concentration of 100,000 cells/ml. After cultured in vitro for 2 days, the TEs were exposed with 100ng/ml TNF-α and cultured for 24 hours, and then underwent a single freeze-thaw cycle by a cryosurgery simulator. With the concentration and duration of TNF-α treatment studied, no apoptotic or necrotic cell death was observed by the administration of TNF-α only. After a freeze/thaw, MCF7 cells within the frozen region of the TEs were significantly injured immediately (i.e. ≤ 20% survival), but gradually repopulated and reached approximately 80% survival in Day3 without TNF-α pre-treatment. MCF7 with TNF-α pre-treatment showed the slight enhancement of immediate injury in the frozen region (i.e. ≤ 10% survival), and the repopulation was significantly inhibited so the viability remained below 40% even in Day 3. These results imply that TNF-α can be a potent adjuvant for cryosurgery.
APA, Harvard, Vancouver, ISO, and other styles
9

Lisin, V. A., V. V. Velikaya, Zh A. Startseva, N. O. Popova, and V. E. Goldberg. "Adjuvant neutron therapy in complex treatment of patients with locally advanced breast cancer." In PHYSICS OF CANCER: INTERDISCIPLINARY PROBLEMS AND CLINICAL APPLICATIONS: Proceedings of the International Conference on Physics of Cancer: Interdisciplinary Problems and Clinical Applications (PC IPCA’17). Author(s), 2017. http://dx.doi.org/10.1063/1.5001624.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Khalil, DN, and JG Schneider. "Abstract P2-09-38: Role of Oncotype 21 Gene Assay and Adjuvant! Online in Breast Cancer Adjuvant Treatment Decisions." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p2-09-38.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer – Adjuvant treatment"

1

Pritchard, Michele. The Preclinical Evaluation of Fever-Range, Whole Body Hyperthermia as an Adjuvant to Chemotherapy and Cytokine Immunotherapy for the Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2000. http://dx.doi.org/10.21236/ada383150.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pritchard, Michele T. The Preclinical Evaluation of Fever-Range, Whole Body Hyperthermia as a Adjuvant to Chemotherapy and Cytokine Immunotherapy for the Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2002. http://dx.doi.org/10.21236/ada407467.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Huang, Li-Bin, Ting-Han Yang, Lie Yang, Yong-Yang Yu, Zi-Qiang Wang, Cun Wang, and Zong-Guang Zhou. Clinical efficacy of adjuvant chemotherapy in the treatment of pT4 Stage II Colon Cancer with defective Mismatch Repair status. A protocol for systematic review and meta-analysis. International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer – Adjuvant treatment' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography